NOTCH3 and ovarian adenocarcinoma: In addition, it was highlighted that the possible association of Notch 3 and stage III/IV of ovarian adenocarcinoma with respect to poorer progression-free survival where 3 out of 5 women with a relapse (within 6 months post-first-line chemotherapy) had Notch 3 overexpression prior to chemotherapy treatment [40].